German independent research institute BioMed X has expanded its immunology research program with Janssen Research & Development of Johnson & Johnson. The new project will focus on the development of novel methodologies to systematically profile and dissect complex tissue microenvironments. The goal is to identify components that induce pro-resolution responses in tissue-resident innate immune cells to restore homeostasis in autoinflammatory diseases such as psoriasis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or inflammatory bowel disease (IBD). The collaboration was facilitated by Johnson & Johnson Innovation.
“We are excited to expand our collaboration with Janssen with a second research project in the field of autoimmune diseases. The new project offers a unique opportunity to develop novel therapeutic concepts and innovative approaches to tackle the most difficult-to-treat autoimmune diseases of our time,” Christian Tidona, Founder and Managing Director of BioMed X Institute said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
An emerging area of science is being focused on identifying strategies to treat patients with autoimmune diseases that not only block inflammation, but which promote pro-resolution responses in immune cells to restore homeostasis.
Recent research findings suggest that tissue factors released during cellular damage, stress or inflammation can trigger pro-resolution responses in innate immune cells without negatively impacting other cell types.